Andrew Miller

1.2k total citations · 3 hit papers
19 papers, 747 citations indexed

About

Andrew Miller is a scholar working on Molecular Biology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Andrew Miller has authored 19 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Psychiatry and Mental health and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Andrew Miller's work include Schizophrenia research and treatment (8 papers), Receptor Mechanisms and Signaling (6 papers) and Ion channel regulation and function (3 papers). Andrew Miller is often cited by papers focused on Schizophrenia research and treatment (8 papers), Receptor Mechanisms and Signaling (6 papers) and Ion channel regulation and function (3 papers). Andrew Miller collaborates with scholars based in United States, Australia and United Kingdom. Andrew Miller's co-authors include Stephen K. Brannan, Alan Breier, Sharon Sawchak, Steven M. Paul, Jeffrey A. Lieberman, Inder Kaul, Steven M. Paul, Christoph U. Correll, Haiyuan Zhu and Samantha E. Yohn and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Andrew Miller

19 papers receiving 730 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

2021 216 citations Stephen K. Brannan, Sharon Sawchak et al. New England Journal of Medicine profile →
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

2023 104 citations Inder Kaul, Sharon Sawchak et al. The Lancet profile →
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia

2024 71 citations Inder Kaul, Sharon Sawchak et al. JAMA Psychiatry profile →

Peers

Countries citing papers authored by Andrew Miller

Since Specialization

Citations

This map shows the geographic impact of Andrew Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Miller more than expected).

Fields of papers citing papers by Andrew Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Miller. The network helps show where Andrew Miller may publish in the future.

Co-authorship network of co-authors of Andrew Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Miller. A scholar is included among the top collaborators of Andrew Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Miller. Andrew Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials 2024 ·CNS Spectrums ·Stephen K. Brannan, Andrew J. Cutler, Sharon Sawchak, Judith C. Kando, Andrew Miller, Amy Claxton, Steven M. Paul, Inder Kaul	1
2	Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials 2024 ·SHILAP Revista de lepidopterología ·Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, (unknown), Rishi Kakar, David P. Walling, Leslie Citrome, Haiyuan Zhu, Andrew Miller, Stephen K. Brannan	13
3	Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials 2024 ·CNS Spectrums ·Inder Kaul, Leslie Citrome, Sharon Sawchak, Judith C. Kando, Andrew Miller, Steven M. Paul, Stephen K. Brannan	1
4	Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials 2024 ·Schizophrenia Research ·William P. Horan, Steven D. Targum, Amy Claxton, Inder Kaul, Samantha E. Yohn, Stephen R. Marder, Andrew Miller, Stephen K. Brannan	26
5	Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia breakdown → 2024 ·JAMA Psychiatry ·Inder Kaul, Sharon Sawchak, David P. Walling, Carol A. Tamminga, Alan Breier, Haiyuan Zhu, Andrew Miller, Steven M. Paul, Stephen K. Brannan	71
6	Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results 2023 ·Psychopharmacology ·Alan Breier, Stephen K. Brannan, Steven M. Paul, Andrew Miller	40
7	Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial breakdown → 2023 ·The Lancet ·Inder Kaul, Sharon Sawchak, Christoph U. Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew Miller, Steven M. Paul, Stephen K. Brannan	104
8	Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study 2022 ·Translational Psychiatry ·Colin Sauder, (unknown), (unknown), Andrew Miller, Steven M. Paul, Stephen K. Brannan	65
9	Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia 2022 ·Schizophrenia ·Christoph U. Correll, (unknown), Andrew Miller, Peter J. Weiden, Stephen K. Brannan	45
10	Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia 2022 ·American Journal of Psychiatry ·Steven M. Paul, Samantha E. Yohn, Michael Popiolek, Andrew Miller, Christian C. Felder	84
11	Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia breakdown → 2021 ·New England Journal of Medicine ·Stephen K. Brannan, Sharon Sawchak, Andrew Miller, Jeffrey A. Lieberman, Steven M. Paul, Alan Breier	216
12	P.0794 KarXT treatment improves cognitive performance in cognitively impaired patients with schizophrenia: a post-hoc analysis of the phase 2 EMERGENT-1 study 2021 ·European Neuropsychopharmacology ·Colin Sauder, (unknown), (unknown), Kiri Granger, (unknown), (unknown), R. Marcus, Sarah E. Paul, Andrew Miller, Stephen K. Brannan	4
13	Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors 2020 ·Current Treatment Options in Oncology ·(unknown), Lauren M. Turner, James Miller, Shelley Ji Eun Hwang, Andrew Miller	11
14	Acquired lipodystrophy associated with immune checkpoint inhibitors 2020 ·Melanoma Research ·(unknown), James Miller, (unknown), (unknown), Shelley Ji Eun Hwang, (unknown), Andrew Miller	24
15	Efficacy and Safety of Xanomeline, a M1/M4 Receptor Preferencing Agonist, Plus Trospium, a Peripheral Muscarinic Antagonist, in Schizophrenia: Phase 2 Clinical Trial Results 2020 ·Biological Psychiatry ·Stephen K. Brannan, Sharon Sawchak, Andrew Miller, Steven M. Paul, Alan Breier	5
16	Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach 2019 ·Journal of Primary Health Care ·(unknown), Sharon Scott, (unknown), (unknown), Andrew Miller, Andrea Taylor, Peter Gow	20
17	Combined immune therapy grade IV dermatitis in metastatic melanoma 2019 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Andrew Miller, Adrienne Morey, (unknown), Desmond Yip	5
18	T106. KARXT: A M1/M4 PREFERRING MUSCARINIC AGONIST FOR THE TREATMENT OF SCHIZOPHRENIA 2019 ·Schizophrenia Bulletin ·Stephen K. Brannan, Andrew Miller, Christian C. Felder, Steven M. Paul, Alan Breier	4
19	Paradoxical psoriasiform reactions of anti‐tumour necrosis factor therapy in inflammatory bowel disease patients 2017 ·Internal Medicine Journal ·(unknown), Andrew Miller, Paul Pavli, Kavitha Subramaniam	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact